The lack of disclosed revenue or earnings limits the ability to assess operational performance. Traders should monitor upcoming 10-K filing for financial details. The biopharma developments are promising but early-stage and not yet cash-generative. The manufacturing acquisitions may provide near-term cash flow, but integration and execution risks remain.
Price Chart
Executive Summary
PMGC Holdings reported a 43% increase in total assets to $12.87 million and a rise in shareholders' equity to $7.84 million for FYE 2025, driven by three acquisitions in precision manufacturing and IT packaging. The company also advanced its biopharma pipeline, with FDA feedback supporting a Phase 2 path for its lead asset EL-22 and new preclinical and licensing activities. However, no revenue or earnings figures were disclosed.
Key Facts
- Total assets grew 43% from $8.99M (FYE 2024) to $12.87M (FYE 2025)
- Shareholders' equity increased from $6.66M to $7.84M
- Completed three acquisitions: Pacific Sun Packaging, AGA Precision Systems, and Indarg Engineering (asset acquisition)
- No revenue, EPS, or profitability metrics were disclosed in the press release
- Biopharma subsidiary Northstrive advanced EL-22 with FDA feedback supporting Phase 2 IND submission
- Preclinical study for EL-32 initiated in March 2026; licensing deal signed with Modulant Biosciences for animal health applications
- AI drug discovery collaboration with Yuva Biosciences in experimental validation phase
Financial Impact
Asset base increased by $3.88 million through acquisitions; no revenue or earnings impact disclosed
Risk Factors
- No revenue or profit data disclosed — inability to assess core business performance
- Biopharma assets are preclinical or early clinical — high risk and long time horizon
- Acquisition-driven growth carries integration and valuation risks
- Market cap of $1M suggests high risk or potential delisting concern
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264501 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 28d ago | Press Release | $3.67 $3.54 | ▼ −3.54% | ▼ −3.34% | $2.58 (−29.70%) |
Sep 18, 2026 5w ago | 8-K | $4.78 $4.42 | ▼ −7.53% | ▼ −9.08% | $2.58 (−46.03%) |
Sep 18, 2026 5w ago | Press Release | $4.78 $4.42 | ▼ −7.53% | ▼ −9.08% | $2.58 (−46.03%) |
Aug 19, 2026 9w ago | Press Release | $0.5603 $0.6100 | ▲ +8.87% | ▲ +9.71% | $2.58 (+360.47%) |
Aug 14, 2026 10w ago | Press Release | $0.9100 $0.8730 | ▼ −4.07% | ▼ −3.59% | $2.58 (+183.52%) |
Jul 29, 2026 12w ago | Press Release | $0.8800 $0.9493 | ▲ +7.88% | ▲ +6.20% | $2.58 (+193.18%) |
Jul 9, 2026 15w ago | 8-K | $1.12 $1.09 | ▼ −2.68% | ▼ −1.91% | $2.58 (+130.36%) |
Jul 1, 2026 16w ago | 8-K | $1.28 $1.18 | ▼ −7.81% | ▼ −7.68% | $2.58 (+101.56%) |
Jun 8, 2026 20w ago | Press Release | $1.59 $1.41 | ▼ −11.32% | ▼ −11.03% | $2.58 (+62.26%) |
Jun 5, 2026 20w ago | 8-K | $1.59 $1.41 | ▼ −11.32% | ▼ −11.03% | $2.58 (+62.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers